Expression of RUNX3 Gene, Methylation Status and Clinicopathological Significance in Breast Cancer and Breast Cancer Cell Lines

Ying Jiang\textsuperscript{a} Dandan Tong\textsuperscript{b} Ge Lou\textsuperscript{a} Ying Zhang\textsuperscript{a} Jingshu Geng\textsuperscript{c}

\textsuperscript{a}Department of Pathology, Second Affiliated Hospital of Harbin Medical University, \textsuperscript{b}Department of Pathology, Basic Medical College, Harbin Medical University, and \textsuperscript{c}Department of Pathology, Third Affiliated Hospital of Harbin Medical University, Harbin, China

**Key Words**
Breast cancer • Methylation • RUNX3 gene • Prognosis

**Abstract**

**Background:** Runt-related transcription factor 3 (RUNX3) is a novel tumor suppressor gene that is frequently silenced by promoter hypermethylation in gastric cancer. In this study, we aimed to analyze the methylation status of the RUNX3 promoter in breast cancer and to evaluate the relationship between RUNX3 expression and breast carcinogenesis and prognosis.

**Methods:** RT-PCR and Western blot were applied on 5 breast cancer cell lines, the human normal breast cell line Hs578Bst and 30 pairs of breast cancer and their matching normal breast tissues to detect mRNA and protein expression of the RUNX3 gene. Methylation-specific PCR was employed to detect the methylation status of the RUNX3 promoter. Immunohistochemical study was performed to analyze RUNX3 protein expression in 88 breast cancer tissues and 40 breast fibroadenomas.

**Results:** The expression of RUNX3 mRNA and protein were negative in 3 breast cancer cell lines (T47D, MCF7 and SKBR3) as analyzed by RT-PCR and Western blotting. Hypermethylation of the RUNX3 promoter was identified in the T47D and MCF7 cell lines, but was not detected in SKBR3. Western blot analysis showed that the RUNX3 protein of 44 kDa was detected in 15 of 30 (50\%) breast cancers. However, RUNX3 protein was detected in all normal breast tissues. Methylation was detected in 13 of the 15 tissues (86.67\%) that did not express RUNX3 protein, but was never detected in any surrounding normal tissues. Immunohistochemistry results revealed that the positive rate of RUNX3 protein expression in breast cancer (35.23\%) was much lower than that in breast fibroadenoma (85\%). RUNX3 expression was correlated with tumor infiltration, clinical stage, lymph node metastasis and the expression of estrogen and progesterone receptor (p < 0.05), but was not related to age, tumor types and pathological grade (p > 0.05).

The survival rate of the patients with RUNX3-positive expression was higher than that with RUNX3-negative expression (p < 0.05).

**Conclusions:** The expression of RUNX3 gene is decreased in breast cancer. The RUNX3 gene may play an important role in the carcinogenesis of breast cancer. The mechanism of its inactivation may be hypermethylation of the promoter. With the increased progression of breast cancer, the expression of RUNX3 protein tends to decrease. The expression of RUNX3 protein has a definite value in judging prognosis in breast cancer.

**Introduction**

Breast cancer is the most common cancer in women both in China and in many other countries. With advances in diagnostic techniques and treatment methods, the prognosis of breast cancer has improved. However, in
China the incidence of breast cancer is increasing. It is necessary to identify the genetic changes in the carcinogenesis and progression of breast cancer.

The Runt family of transcription factors consists of 3 members, RUNX1 (PEBP2aB/COFB1/AML1), RUNX2 (PEBP2aA/COFB1/AML3) and RUNX3 (PEBP2aC/COFB3/AML2) [1]. All 3 RUNX family members play important roles in normal developmental processes and in carcinogenesis [2–4]. RUNX3 is an integral component of a signaling cascade mediated by transforming growth factor-β (TGF-β) [5]. Li et al. [6] reported that the RUNX3 protein has essential functions in both cell proliferation and differentiation in gastric epithelium. The gastric epithelium of RUNX3 knockout mice demonstrated hyperplasia and a reduced rate of apoptosis, accompanied by a reduced sensitivity to TGF-β. Interestingly, 1p36, where RUNX3 maps according to Bae et al. [7], is a region commonly deleted in a wide variety of human carcinomas, including breast cancer [8]. Therefore, it is of great interest to examine whether inactivation of RUNX3 occurs in breast cancer as well.

In the present study, 5 breast cancer cell lines and 30 paired breast cancer and normal tissues were tested for the methylation status of the RUNX3 gene promoter. We also examined the expression of RUNX3 protein and mRNA both in the breast cancer cell line and breast cancer tissues. In addition, we analyzed the relationship between RUNX3 expression and clinicopathological features in breast cancer.

### Materials and Methods

#### Cell Lines and Culture Conditions

The human breast cancer cell lines (Bcap37, BT549, SKBR3, MCF7 and T47D) and the human normal breast cell line HS578Bst were obtained from Cell Bank, Chinese Academy of Sciences, Shanghai, China. All cell lines were maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air, in RPMI 1640 (Gibco-BRL, Tokyo, Japan) supplemented with 10% fetal bovine serum.

#### Human Tissue Specimens and Patient Information

We obtained frozen tissue samples of 30 pairs of breast cancer and their matching normal breast tissues from the Second Affiliated Hospital of Harbin Medical University. Eighty-eight formalin-fixed, paraffin wax-embedded tissues of human breast cancer resected in 2000–2001 were retrieved from the Pathology Department of the Second Affiliated Hospital of Harbin Medical University. Paraffin blocks were sectioned in 4-μm slices and stained with hematoxylin and eosin. We obtained 40 breast fibroadenoma tissues as benign tumor controls. All patient information was obtained. The tumors were classified by 2 experienced pathologists according to the WHO standard. The patients had a well-documented clinical history and follow-up information. None of them underwent preoperative chemotherapy and/or radiotherapy. Details of the patients’ characteristics are provided in table 1.

#### RT-PCR Assay for RUNX3

An RT-PCR assay was used to examine RUNX3 mRNA expression. Total RNA was extracted from samples with Trizol reagent (Invitrogen, Carlsbad, Calif., USA) and cDNA was synthesized from total RNA with oligo-dT primer (Reverse Transcription System; Promega, Madison, Wisc., USA) following the manufacturer’s instructions. Primer sequences for RUNX3 amplification were: forward, 5’-CTCATGAAGACACAGGGTG-3’; reverse, 5’-AGGTAGTTGCTGGAGAAGC-3’ (GenBank accession No. NM_004350.1). The PCR reactions were performed in a thermal cycler (GeneAmp RCR System 9600; Applied Biosystems, Shanghai, China). The human breast cancer cell lines (Bcap37, BT549, SKBR3, MCF7 and T47D) and the human normal breast cell line HS578Bst were obtained from Cell Bank, Chinese Academy of Sciences, Shanghai, China. All cell lines were maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air, in RPMI 1640 (Gibco-BRL, Tokyo, Japan) supplemented with 10% fetal bovine serum.

### Table 1. Relationship between RUNX3 expression and clinicopathological data in 88 breast cancers

<table>
<thead>
<tr>
<th>Variables</th>
<th>Total (n = 88)</th>
<th>RUNX3 expression</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27–52 years</td>
<td>45</td>
<td>17</td>
<td>28</td>
</tr>
<tr>
<td>53–83 years</td>
<td>43</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>Tumor types</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ductal carcinoma</td>
<td>57</td>
<td>18</td>
<td>39</td>
</tr>
<tr>
<td>Lobular carcinoma</td>
<td>31</td>
<td>13</td>
<td>18</td>
</tr>
<tr>
<td>Tumor infiltrating</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carcinoma in situ</td>
<td>18</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>Invasive carcinoma</td>
<td>70</td>
<td>20</td>
<td>50</td>
</tr>
<tr>
<td>Carcinoma in situ</td>
<td>11</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>DCIS</td>
<td>7</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Invasive carcinoma</td>
<td>46</td>
<td>14</td>
<td>32</td>
</tr>
<tr>
<td>IDC</td>
<td>24</td>
<td>6</td>
<td>18</td>
</tr>
<tr>
<td>I</td>
<td>14</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>II</td>
<td>20</td>
<td>6</td>
<td>14</td>
</tr>
<tr>
<td>III</td>
<td>12</td>
<td>3</td>
<td>9</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>41</td>
<td>8</td>
<td>33</td>
</tr>
<tr>
<td>Negative</td>
<td>47</td>
<td>23</td>
<td>24</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>52</td>
<td>24</td>
<td>28</td>
</tr>
<tr>
<td>III–IV</td>
<td>36</td>
<td>7</td>
<td>29</td>
</tr>
<tr>
<td>ER expression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>++</td>
<td>40</td>
<td>21</td>
<td>19</td>
</tr>
<tr>
<td>– or +</td>
<td>48</td>
<td>10</td>
<td>38</td>
</tr>
<tr>
<td>PR expression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>++</td>
<td>42</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>– or +</td>
<td>46</td>
<td>9</td>
<td>37</td>
</tr>
</tbody>
</table>

DCIS = Ductal carcinoma in situ; LCIS = lobular carcinoma in situ; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma.
Foster City, Calif., USA). The amplification program for the RUNX3 transcript was 30 s at 94°C, 30 s at 56°C and 50 s at 72°C for 30 cycles. The housekeeping gene β-actin was used as an internal control to confirm the success of the RT reaction. Primer sequences for β-actin amplification were: forward, 5'-AATGGGTTGTTGGAACATGACTT-3'; reverse, 5'-TCAATGACATTGCTCAGCAG-3'. These primer sequences were identical to the endogenous human target genes as confirmed by a BLAST search.

PCR products were analyzed on 2% agarose gels.

DNA Extraction and Methylation-Specific PCR

Genomic DNA was obtained from cell lines and primary cancers by digestion with proteinase K (Sigma, St. Louis, Mo., USA), followed by phenol/chloroform (1:1) extraction [9]. DNA methylation patterns in the CpG island of RUNX3 were determined by the methylation-specific PCR (MSP) method as reported by Herman et al. [10]. Briefly, 4 μg genomic DNA was denatured by NaOH and modified by sodium bisulfite. The modified DNA was purified using a Wizard DNA purification kit (Promega), treated with NaOH to desulfonate, precipitated with ethanol and resuspended in water. PCR amplification was performed with bisulfite-treated DNA as a template using specific primer sequences for the methylated and unmethylated forms of the genes. Primer sequences of RUNX3 for methylated reaction were as follows: forward, 5'-ATAAGCGGTCGTTAGGGCGTCG-3'; reverse, 5'-GCTTCTACTTTCCCACTTCTCACA-3'. Those for the unmethylated reaction were: forward, 5'-ATAATAGTGGTTGTTAGGGTGTTG-3'; reverse, 5'-ACTTCTACTTTCCCACTTCTCACA-3'.

Step-down PCR reactions were performed in a 20-μl reaction volume containing 10× buffer (including MgCl₂) 2 μl, dNTP 2 μl, 0.5 μl of each PCR primer, 0.5 μl of AmpliTaq polymerase, 2 μl of bisulfite-modified DNA and 12.5 μl diethyl pyrocarbonate-treated water. Reactions were hot started at 95°C for 2 min. This was followed by 35 cycles at 95°C for 30 s, 55°C for 30 s and 72°C for 45 s, followed by a 7-min extension at 72°C. The amplification products were separated on a 2% agarose gel and visualized by UV transilluminatiion.

DNA from peripheral blood lymphocytes (n = 10) from healthy subjects was used as negative control. DNA from lymphocytes of a healthy volunteer treated with Ss1 methyltransferase (Sigma) and then subjected to bisulfate treatment was used as a positive control for methylated alleles. Results were confirmed by repeating bisulfite treatment and MSP for all samples.

Western Blot Analysis

Whole-cell lysates were prepared from tissue specimens or cell culture. Samples were boiled in SDS sample buffer for 5 min before running on a 10–20% SDS polyacrylamide gel. After blocking the blot in 3% BSA for 2 h at room temperature, the membrane was blotted with anti-β-actin monoclonal antibody (1:1,000; Sigma) and anti-RUNX3 polyclonal antibody (1:500; Actiivenotif, Carlsbad, Calif., USA). Horseradish peroxidase-conjugated secondary antibodies were incubated with the blot at 1:1,000 dilution for 1 h at room temperature. After extensive washing, specific bands were detected using an enhanced chemiluminescence system (ECL Detection System; Amersham Biosciences, Uppsala, Sweden).

Immunohistochemistry

Sections (4 μm thick) of formalin-fixed, paraffin-embedded tumor specimens were prepared and processed as previously described [11]. RUNX3 protein expression was detected with a rabbit polyclonal antibody against human RUNX3 (Activemotif). The antibody was in a 1:150 dilution. A positive reaction was indicated by a reddish brown precipitate in the nucleus. RUNX3 immunoreactivity was classified into 2 groups: negative expression, when the positive cells were less than 10%, and positive expression, when the positive cells were 10% or more. Estrogen receptor (ER) and progesterone receptor (PR) protein expression were detected with a mouse monoclonal antibody against human. Depending on the percentage of positive cells and staining intensity, ER and PR expression were classified into 4 groups: negative (less than 10% positive cells), + (10–50% positive cells), ++ (51–75% positive cells) and +++ (76% or more positive cells). Two independent investigators scored the sections without the knowledge of patient outcome (double blinded). An average value of 2 independent scores is given in the present study.

Statistics

The χ² test was performed to determine the significance of the difference between the covariates. Survival durations were calculated with the Kaplan-Meier method. The log-rank test was used to compare the cumulative survival durations in the patient groups. The Cox proportional hazards model was used to compute univariate and multivariate hazards ratios for the study variables. The patients’ level of RUNX3 expression, lymph node status, ER and PR status and histopathological grade were included in the model. p < 0.05 was defined as being statistically significant. The SPSS software (version 11.05; SPSS Inc., Chicago, Ill., USA) was used for the analyses.

Results

The Expression of RUNX3 mRNA and Protein in Breast Cancer Cell Lines

We examined the expression of RUNX3 mRNA in breast cancer cell lines by RT-PCR. As shown in figure 1a, the expression of RUNX3 mRNA was undetectable in the T47D, MCF7 and SKBR3 cell lines, while control reaction products (β-actin) were detected in all cell lines. Next, Western blot analysis was done on the same panel of breast cells to determine whether alterations in mRNA expression of RUNX3 were accompanied by corresponding changes at the protein level as well. The expression of RUNX3 protein was detected in Bcap37, BT549 and the human normal breast cell line Hs578Bst (fig. 1b). The level of RUNX3 mRNA expression correlated with the level of RUNX3 protein. Overall, of the 5 cancer cell lines tested, 3 (60%) did not express RUNX3 at mRNA and protein levels.

RUNX3 Expression and Localization in Breast Cancer Tissues

RUNX3 expression was evaluated in 88 human breast cancers and 40 breast fibroadenomas by immunohisto-
chemistry. Positive expression of RUNX3 protein was found in 31 (35.23%) and 40 (100%) breast cancer and breast fibroadenoma cases, respectively. There was a significantly lower level of RUNX3 expression in the cancers than in the benign tumors (p < 0.01). The representative pictures are shown in figure 2. To further confirm these observations, RT-PCR and Western blot assay were performed using 30 pairs of breast cancer and their matching normal breast tissues.

Western blot analysis disclosed that the RUNX3 protein of 44 kDa was detected in 15 of 30 (50%) breast cancers, but was detected in all normal breast tissues. RT-PCR was performed as well. Of the 30 cancer tissues, 16 (53.33%) expressed RUNX3 mRNA. Only 1 case that expressed RUNX3 mRNA did not express RUNX3 protein, as shown by Western blot analysis. On the other hand, all normal breast tissues expressed RUNX3 mRNA. The results of the RT-PCR and the Western blot analysis were consistent with those of the immunohistochemistry analysis. These results showed that RUNX3 was commonly expressed in normal human breast tissues and benign breast tumors, but decreased or absent in breast cancers.

By immunohistochemistry analysis, we also found that the RUNX3-positive staining of all breast fibroadenomas and normal breast ducts adjacent to the cancers in the cancer tissues was located at nuclear regions. We found 4 types of staining patterns for RUNX3 in breast cancer tissues: (1) negative in both the nucleus and the cytoplasm (negative, 49 cases), (2) positive in the nucleus and negative in the cytoplasm (positive, 28 cases), (3) positive in the nucleus and the cytoplasm (positive, 3 cases) and (4) positive in the cytoplasm and negative in the nucleus (negative, 8 cases). There was no different staining pattern between invasive components and noninvasive components in the 11 cancer tissues with RUNX3 protein cytoplasm staining.

**Frequent Hypermethylation of the RUNX3 Gene in Breast Cancer**

To investigate whether the gene silencing was because of hypermethylation of RUNX3, MSP was performed in 5 breast cancer cell lines, the normal breast cell line Hs578Bst and 30 primary breast cancer tissues and corresponding normal tissues. We found that 2 kinds of cells (T47D and MCF7) exhibited CpG island methylation in the RUNX3 promoter (fig. 3).

In tumor tissues, methylation was detected in 13 of the 15 tissues (86.67%) that did not express RUNX3 protein, but was never detected in any surrounding normal tissues. In normal tissue samples, unmethylated DNA was amplified in all 30 samples. Of 9 stage III cases, 7 (77.78%) showed RUNX3 methylation. For stage I and II cases, 2 of 9 (22.22%) and 4 of 12 (33.33%) exhibited RUNX3 methylation, respectively. Of 13 RUNX3-methylated cases, 9 (69.23%) were with lymph node metastasis. These results indicate that RUNX3 is silenced in approximately 43.33% (13/30) of breast cancers due to hypermethylation in the promoter region, and RUNX3 methylation was detected mostly in advanced-stage (III) cancer specimens.

**The Correlation between RUNX3 Expression and Clinicopathological Parameters**

We examined the relationship between RUNX3 expression and clinicopathological features in 88 breast cancer samples by immunohistochemistry. RUNX3 expression was not associated with age, tumor types and pathological grade, but it was associated with clinical stage and lymph node metastasis. The expression of RUNX3 protein was higher in the early-stage cases than in the advanced-stage breast cancer cases. The expression of RUNX3 protein was lower in the presence of lymph node metastasis cases than in their absence. In addition, the expression of
Fig. 2. Immunohistochemical analysis of RUNX3 expression using a rabbit polyclonal antibody against human RUNX3. RUNX3 expression is detected in the nucleus in the normal breast tissue adjacent to the cancer (a) and breast fibroadenoma tissue (b). c The positive expression of RUNX3 in ductal carcinoma in situ tissue was stained in part of nuclei. d RUNX3 expression in invasive ductal carcinoma was not nuclear but cytoplasmic staining.

Fig. 3. Methylation analysis of RUNX3 gene in 5 human breast cancer cell lines and Hs578Bst. The promoter region of RUNX3 gene was methylated in 2 cancer cell lines (MCF7 and T47D). A and B were unmethylated and methylated PCR controls of the RUNX3 gene, respectively. M = Methylation products; U = unmethylation products.
RUNX3 protein was higher in ER- and PR-positive cases than in ER- and PR-negative cases (table 1).

Survival Analysis of Breast Cancer Patients
Kaplan-Meier survival curves showed that the 5-year survival rate was 83.87% in the 31 patients with positive RUNX3 expression and 54.39% in the 57 patients with negative RUNX3 expression, the value being significantly different ($p < 0.005$; fig. 4). In a Cox proportional hazards model for multivariate analysis, the reduced RUNX3 expression was an independent predictor of inferior survival after we adjusted the effect of the covariates including the patients’ RUNX3 expression level, lymph node status, ER and PR status, histopathological grade, age and sex. The odds ratio in the group with negative (3.017, 95% confidence interval 1.136–16.325) RUNX3 expression was significantly higher than that in the group with positive RUNX3 expression.

Discussion
The RUNX3 gene is located on human chromosome 1p36, a region that has long been suspected to harbor one or more suppressors of various tumors [8, 12–13]. Recent studies suggested that RUNX3 has been implicated as a tumor suppressor in several tumors, including gastric cancer, colorectal cancer, hepatocellular cancer and esophageal squamous cell carcinoma among others [6, 14–16]. The effect of RUNX3 on breast cancer has not been clearly studied. In this study, we have demonstrated that the expression of RUNX3 decreased in breast cancer tissues and breast cancer cell lines, whether analyzed by Western blot, RT-PCR or immunohistochemistry. This indicated that inactivation of RUNX3 may play an important role in tumorigenesis of breast carcinomas.

Although the importance of genetic mutation in carcinogenesis has long been recognized, DNA methylation has also been a powerful mechanism for suppression of gene activity [17–19]. More and more studies have revealed that hypermethylation of the CpG island in the promoter region is an alternative way to silence some cancer-associated genes. To date, many genes, such as RB, p16, E-cadherin, HIN-1 and RASSF1A, have been shown to be inactivated by hypermethylation in various tumors [20–24]. Li et al. [6] reported that RUNX3 is frequently inactivated in gastric cancer cell lines by hypermethylation of CpG islands in the exon 1 region. Therefore, RUNX3 seems to be a new tumor suppressor gene that is silenced by promoter hypermethylation in cancer cells. In the present study, we found that hypermethylation of the RUNX3 promoter region occurred in 13 of 30 (43.33%) breast cancer tissues and 2 (T47D and MCF7) of 5 breast cancer cell lines (40%) by using MSP. In addition, we found the 2 cancer cell lines that had hypermethylation in the CpG island of the RUNX3 promoter region did not express RUNX3 mRNA or protein, whereas high expression was observed in the cancer cell lines (Bcap37 and BT549) with no methylation of the same region. This result indicates that the methylation status of the RUNX3 promoter region correlates inversely with the expression of RUNX3. But SKBR3, where RUNX3 mRNA and protein were negative expressed, did not exhibit CpG island methylation in the RUNX3 promoter. This was in accordance with the findings of Lau et al. [25]. This suggests that other mechanisms may be involved in the regulation of RUNX3 expression.

In cancer tissues, methylation status of the RUNX3 promoter region correlates inversely with the expression of RUNX3, too. According to our statistical analysis of clinicopathological data, hypermethylation of the RUNX3 promoter region was found to be significantly higher in the advanced stage in breast cancer. These results indicate that hypermethylation of the RUNX3 promoter region is associated with the loss of RUNX3 protein expression. RUNX3 acts as a possible potent tumor suppressor gene in breast cancers, as well as in gastric cancers.
Immunohistochemistry results revealed that the positive rate of RUNX3 expression in breast cancers was much lower than that in benign breast tumors. The decrease in RUNX3 expression was inversely correlated with clinical stage and lymph metastasis. Interestingly, it was observed that the expression of RUNX3 protein was increased in the ER- and PR-positive cases. The mechanism is not clear and needs to be further studied. Lower levels of RUNX3 in human breast cancer are significantly associated with a worse patient survival. RUNX3 was an independent predictor of poor patient outcome.

Ito et al. [26] reported that RUNX3 expression mislocalized from the nucleus to the cytoplasm in gastric cancer. Lau et al. [25] yielded a similar result in breast cancer. In the present study, we also examined the protein localization of RUNX3. We observed cytoplasmic localization of RUNX3 in 11 cases of breast cancers. However, nuclear expression of RUNX3 is very strong in all breast fibroadenomas and normal breast ducts found in the cancer tissues. In many signaling pathways, the nuclear import of transcription factors is an essential element. Transcription factors localized in the cytoplasm are thought to be in a basal, inactive state. RUNX3 localized in the cytoplasm cannot act as a transcription factor and does not elicit tumor-suppressive effects [26]. Cytoplasmic retention of RUNX3 may result from the absence of downregulation of one or more components of a signaling pathway required for RUNX3 nuclear translocation. The importance of the nuclear localization of RUNX3 is clear, but the mechanisms need further study.

In summary, our findings demonstrate 2 points about the relationship between RUNX3 and breast cancer. First, RUNX3 expression in breast cancer is very low both at mRNA and protein level. A poor prognosis in breast cancer is associated with a lower expression of RUNX3. Second, methylation of the RUNX3 promoter region occurs commonly both in cell lines and in primary breast cancers. The aberrant methylation of RUNX3 is tumor specific, since it was not observed in normal breast tissues and breast normal cell line. Methylation is correlated with the silencing of RUNX3 expression. These results suggest that the loss of RUNX3 expression caused by hypermethylation is frequently associated with the evolution of breast cancer. RUNX3 may be a candidate for prognosis and molecular target therapy.

Acknowledgement

This work was supported in part by a Grant-in-Aid for Scientific Research from the Department of Education of Heilongjiang (grant No. 11521080).

References